Valuation: Roche Holding AG

Capitalization 255B 326B 279B 242B 448B 31,184B 452B 3,049B 1,184B 14,818B 1,224B 1,198B 51,577B P/E ratio 2026 *
16.9x
P/E ratio 2027 * 15.8x
Enterprise value 266B 339B 291B 252B 466B 32,442B 470B 3,172B 1,232B 15,416B 1,273B 1,246B 53,659B EV / Sales 2026 *
4.24x
EV / Sales 2027 * 3.97x
Free-Float
88.75%
Yield 2026 *
3.13%
Yield 2027 * 3.21%

Last Transcript: Roche Holding AG

1 day+3.62%
1 week-0.94%
Current month-0.97%
1 month-0.88%
3 months-12.42%
6 months+10.21%
Current year-3.93%
1 week 313
Extreme 313
323.2
1 month 312
Extreme 312
326.7
Current year 291
Extreme 291
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5d. change 1-year change 3-years change Capi.($)
+3.60%-0.94%+23.89%+10.73% 326B
+0.58%+6.72%+38.04%+132.95% 898B
-0.62%+3.86%+53.65%+44.07% 556B
+0.66%+5.20%+16.71%+44.64% 372B
-0.87%+2.10%+34.33%+13.53% 287B
+0.70%+3.79%+30.24%+27.21% 285B
-1.00%+0.71%+49.96%-3.61% 280B
+0.91%+1.25%-30.88%-49.10% 207B
-1.44%-0.58%+21.45%+41.29% 181B
-1.39%-0.89%+29.72%+66.07% 164B
Average +0.12%+1.74%+26.71%+32.78% 355.64B
Weighted average by Cap. +0.28%+2.19%+31.72%+51.38%

Financials

2026 *2027 *
Net sales 62.71B 80.06B 68.59B 59.39B 110B 7,655B 111B 748B 291B 3,637B 300B 294B 12,661B 65.29B 83.35B 71.41B 61.83B 114B 7,969B 115B 779B 303B 3,787B 313B 306B 13,181B
Net income 15.33B 19.57B 16.76B 14.51B 26.87B 1,871B 27.09B 183B 71.05B 889B 73.43B 71.86B 3,094B 16.38B 20.92B 17.92B 15.52B 28.73B 2,000B 28.96B 196B 75.95B 950B 78.5B 76.82B 3,308B
Net Debt 10.31B 13.17B 11.28B 9.77B 18.08B 1,259B 18.23B 123B 47.81B 598B 49.41B 48.35B 2,082B 3.44B 4.39B 3.76B 3.26B 6.03B 420B 6.08B 41.03B 15.94B 199B 16.47B 16.12B 694B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-05-07 315.30 CHF -0.94% 590,249
26-05-13 320.00 CHF -0.47% 611,255
26-05-12 321.50 CHF +0.66% 654,692
26-05-11 319.40 CHF +1.30% 724,136
26-05-08 315.30 CHF -0.94% 590,249
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
320.00CHF
Average target price
360.76CHF
Spread / Average Target
+12.74%

Quarterly revenue - Rate of surprise